American Association for Cancer Research
Browse
mcr-23-0049_supplemental_figure_3_suppsf3.pdf (482.21 kB)

Supplemental Figure 3 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells

Download (482.21 kB)
journal contribution
posted on 2023-07-19, 15:00 authored by Haowen Jiang, Clifford Jiajun He, Albert M. Li, Bo He, Yang Li, Meng-Ning Zhou, Jiangbin Ye

S3. Mitochondrial uncoupler FCCP and BAM5 inhibit reductive carboxylation.

History

ARTICLE ABSTRACT

When the electron transport chain (ETC) function is impaired, cancer cells rely on reductive carboxylation (RC) to convert α-ketoglutarate (αKG) to citrate for macromolecular synthesis, thereby promoting tumor growth. Currently, there is no viable therapy to inhibit RC for cancer treatment. In this study, we demonstrate that the mitochondrial uncoupler treatment effectively inhibits RC in cancer cells. Mitochondrial uncoupler treatment activates the ETC and increases the NAD+/NADH ratio. Using U–13C-glutamine and 1–13C-glutamine tracers, we show that mitochondrial uncoupling accelerates the oxidative tricarboxylic acid (TCA) cycle and blocks RC under hypoxia, in von Hippel-Lindau (VHL) tumor suppressor–deficient kidney cancer cells, or under anchorage-independent growth condition. Together, these data demonstrate that mitochondrial uncoupling redirects α-KG from RC back to the oxidative TCA cycle, highlighting that the NAD+/NADH ratio is one key switch that determines the metabolic fate of α-KG. Inhibiting RC could be a key mechanism by which mitochondrial uncouplers inhibit tumor growth. Mitochondrial uncoupling is a novel strategy to target RC in cancer.

Usage metrics

    Molecular Cancer Research

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC